European Survey of Prescriber Understanding of Risks Associated with Retigabine

Background We conducted a survey to assess physicians’ knowledge and understanding of key risks associated with retigabine. Objective The survey evaluated the effectiveness of the educational plan for retigabine, as specified in the GlaxoSmithKline (GSK) European Risk Management Plan. Methods This w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs - real world outcomes Jg. 2; H. 4; S. 345 - 353
Hauptverfasser: Ishihara, Lianna, Lewis, Anne, Kolli, Sathish, Brickel, Neil
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Cham Springer International Publishing 01.12.2015
Springer Nature B.V
Schlagworte:
Confidence intervals
Convulsions & seizures
Drug dosages
Internal Medicine
Medicine
Medicine & Public Health
Multiple choice
Performance evaluation
Pharmacology/Toxicology
Pharmacotherapy
Physicians
Questionnaires
Short Communication
United Kingdom > UK
United States > US
Norway
Europe
Denmark
Slovakia
Switzerland
Germany
Spain
Educational Plan
Central Nervous System Side Effect
Retigabine
Eligible Respondent
Associate Confidence Interval
ISSN:2199-1154, 2198-9788
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background We conducted a survey to assess physicians’ knowledge and understanding of key risks associated with retigabine. Objective The survey evaluated the effectiveness of the educational plan for retigabine, as specified in the GlaxoSmithKline (GSK) European Risk Management Plan. Methods This was a cross-sectional survey of physicians across seven European countries (Denmark, Germany, Norway, Slovakia, Spain, Switzerland, and the UK) who had prescribed an antiepileptic drug at least once within the past 3 months, and to whom a letter containing the retigabine Physician’s Guide was sent. The survey included multiple-choice and closed-ended questions. Primary outcome was the proportion of physicians correctly answering questions related to retigabine-associated risks. Point estimates for the proportion of correct responses and associated confidence intervals were calculated. Results Overall, 294 prescribers completed the survey between November 2012 and October 2013. Generally, physicians had adequate knowledge of the retigabine indication (78–92 % correct responses). Specific dose-related knowledge (57–74 %) and management of individual risks (20–77 %) were recalled less well. Subgroup analyses showed that both the 189 physicians who read the retigabine education letter and the 144 who had prescribed retigabine had better recall of the risks associated with retigabine (20–78 %) than those who did not. Conclusions Overall, physicians were aware, to varying degrees, of the risks associated with retigabine. Subsequent to the conduct of this survey, GSK has made further changes to the product labeling for retigabine, sent an updated ‘Dear Healthcare Professional’ letter, and initiated another EU survey to assess how effectively specific risks associated with retigabine use are communicated. Clinical trials registration number NCT01721213.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2199-1154
2198-9788
DOI:10.1007/s40801-015-0044-3